News
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More